Mirum Pharmaceuticals Overview

  • Founded
  • 2018
Founded
  • Status
  • Public
  • Employees
  • 85
Employees
  • Stock Symbol
  • MIRM
Stock Symbol
  • Share Price
  • $18.00
  • (As of Tuesday Closing)

Mirum Pharmaceuticals General Information

Description

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Pending Transaction (M&A)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 950 Tower Lane
  • Suite 1050
  • Foster City, CA 94404
  • United States
+1 (650) 000-0000

Mirum Pharmaceuticals Timeline

201920202021
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mirum Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$18.00 $17.75 $15.22 - $27.43 $541M 30.5M 95.6K -$4.90

Mirum Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 374,362 393,037 438,911
Revenue 0 0 0
EBITDA (129,076) (103,865) (54,440)
Net Income (132,492) (103,270) (52,553)
Total Assets 222,241 240,864 146,712
Total Debt 3,105 3,263 3,648
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mirum Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mirum Pharmaceuticals‘s full profile, request access.

Request a free trial

Mirum Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Mirum Pharmaceuticals‘s full profile, request access.

Request a free trial

Mirum Pharmaceuticals Executive Team (11)

Name Title Board Seat Contact Info
Christopher Peetz Chief Executive Officer & Founder
Ian Clements Chief Financial Officer, Finance
Paul Ross Chief Compliance Officer
Pamela Vig Ph.D Chief Scientific Officer
Lara Longpre Executive
You’re viewing 5 of 11 executive team members. Get the full list »

Mirum Pharmaceuticals Board Members (11)

Name Representing Role Since
Edward Mathers Self Board Member 000 0000
Laura Brege Self Board Member 000 0000
Laurent Fischer MD Self Board Member 000 0000
Niall O'Donnell Ph.D RiverVest Venture Partners Board Member 000 0000
Patrick Heron Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Mirum Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mirum Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mirum Pharmaceuticals‘s full profile, request access.

Request a free trial